Kymera Therapeutics announces first patient dosed in BROADEN2 Phase 2b trial

Kymera Therapeutics (KYMR) announced that it recently initiated dosing in its BROADEN2 Phase 2b clinical trial evaluating KT-621, an oral, highly selective, potent degrader of STAT6, in patients with moderate to severe atopic dermatitis. The Company expects to report data from the BROADEN2 trial by mid-2027. Additionally, the Company previously announced it completed dosing in the KT-621 BroADen Phase 1b trial in AD, with data to be reported in December 2025. “The initiation of dosing in the BROADEN2 trial represents a major step in the advancement of our first-in-industry STAT6 degrader program and reflects the continued progress of our translational strategy, building a robust foundation for future development across multiple Type 2 diseases,” Jared Gollob, MD, Chief Medical Officer, Kymera Therapeutics. “With additional key clinical milestones on the horizon – including the BroADen Phase 1b data in December and BREADTH Phase 2b asthma trial launch in the first quarter of 2026 – we remain focused on realizing the promise of KT-621 as a potential first-in-class oral treatment option for millions of patients living with chronic immunological diseases.”